A Message from Dr. Nancy Mendenhall In this issue, we invite you to delve further into the importance of our Primary Completion Date (PCD) on February 15, 2026. As we look ahead to this milestone, we also recognize the vital role each participant plays in helping to generate…
A Message from Dr. Nancy Mendenhall Over the past two years, we have been searching for funding opportunities to support another 5 years of follow-up for the COMPPARE cohorts to provide all participants with a minimum of 8 years of follow-up. This spring a new funding opportunity was…
A Message from Dr. Nancy Mendenhall Since COMPPARE was launched in 2017, new information has emerged that suggests there may be other differences in outcomes between photon and proton radiation in prostate cancer. We would like to answer as many of these questions as…
COMPPARE Newsroom Prostate cancer research news…
A Message from Dr. Nancy Mendenhall I am excited to share with you that on October 31, 2022, COMPPARE closed enrollment with a total of 2,524 participants (1,024 photon patients and 1,500 proton patients; 900 pragmatic, 600 randomized)! Read Dr. Mendenhall’s message. Partner Site…
A Message from Dr. Nancy Mendenhall As we near the completion of COMPPARE’s overall enrollment objective – a total of 3,000 patients – we are beginning to reflect and evaluate what we’ve learned thus far in creating and carrying out a large, multi-institutional pragmatic…
A Message from Dr. Nancy Mendenhall Our focus on IMRT enrollment has increased as we have become more aware of practice pattern changes that have impacted IMRT accrual, specifically the increased utilization of ultra-hypofractionated radiation (stereotactic body radiation therapy, or SBRT). Read Dr. Mendenhall’s message.
On November 17, Dr. Nancy Mendenhall, COMPPARE Principal Investigator, and Charles Griggs, Minority Engagement Group Coordinator, participated in a special panel discussion entitled “From Principles to Practice: Building Partnerships for Trust and Equity in Health Research” during the 7th annual meeting of the Patient-Centered Outcomes Research Institute (PCORI). “This year’s…
A Message from Dr. Nancy Mendenhall COMPPARE has achieved both a remarkable overall accrual rate and a remarkable accrual rate of minorities. In fact, the study stands to become a model for patient-centric clinical research in the future. Read Dr. Mendenhall’s message. Partner Site…
A Message from Dr. Nancy Mendenhall As we look forward to the normal resumption of our work, we ask you to join us in an effort to encourage all men to get back to having their prostates checked annually in order to detect cancers…
